ALFA Finder| Management target | Revenue 10.0% FY27 |
|---|
| Revenue growth | 20% YoY increase to 384 Cr total revenue. |
|---|---|
| Margins | EBITDA margin at 17%; 180 bps improvement QoQ. |
| Demand visibility | Strong momentum in base business supported by new pipeline. |
| Management confidence | Balanced; optimistic on base business, cautious on Ibuprofen headwinds. |
Growth
Revenue grew 20% YoY to 384 Cr, driven by strong 24% base business growth.
Outlook
Management targeting 10% base business growth and becoming net-debt-free by FY29.
Risks
Ibuprofen remains loss-making with -12% margins; West Asia crisis creates supply chain vulnerability.
Last quarter's promises, checked
Delivered
- Debt reduction of 158 Cr → delivered 135 Cr + 113 Cr rights (= BEAT)
- Base business EBITDA margin 25% → delivered 26% (= BEAT)
- Q4 revenue momentum → delivered 20% YoY growth to 384 Cr (= BEAT)
Partly delivered
- Targeting debt-free by FY29 → reduced debt to ~503 Cr (= PARTIAL)
Missed
- Ibuprofen strategic options in 2 quarters → remains loss-making/unresolved (= MISS)
Earnings Call Transcript filed with BSE, NSE: SOLARA. Summary written with AI assistance from the document.
Solara Active Pharma Sciences Ltd: key numbers
- Share price
- ₹668.45
- Market cap
- ₹3,220 Cr
- Revenue (annual)
- ₹1,369 Cr
- Net profit (annual)
- ₹-7.41 Cr
- P/E (TTM)
- 87.2×Sector 43.8×
- Promoter holding
- 41.93%+0.00% QoQ
- FII holding
- 10.71%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Solara Active Pharma Sciences Ltd
All →Solara Active Pharma Sciences Other Announcement
Solara Active Pharma Sciences Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026. This disclosure details equity ownership across various investor categories.
Solara Active Pharma Sciences Earnings Call Transcript: Key Takeaways
Solara delivered its best profitability in five years despite ongoing Ibuprofen pricing and raw material challenges.
Solara Active Pharma Sciences Investor Presentation: Key Takeaways
Solara's Q2 FY27 delivered record EBITDA and PAT in five years, driven by 33% revenue growth. Base business strength offset Ibuprofen headwinds, which is now nearing breakeven.
Solara Active Pharma Sciences Employee Stock Options
Solara Active Pharma Sciences Limited allotted 8,300 equity shares under its 2018 ESOP plan. The exercise of these options realized Rs. 0.31 Crore for the company.
- Value
- ₹0.31 Cr
Solara Active Pharma Sciences Q2 FY27 Results: Turns Profitable, Net Profit ₹28.5 Cr
Solara Active Pharma Sciences Ltd reported revenue from operations of ₹417.3 Cr (+33.1% YoY) and net profit of ₹28.5 Cr for Q2 FY27.
- Key figure
- Net profit ₹28.5 Cr
Solara Active Pharma Sciences Other Announcement
Solara Active Pharma received an ESG rating of 63 ('Strong' category) from Crisil ESG Ratings for the fiscal year 2026, an upgrade from the prior year.